TipRanks

Notifications

Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP)

Analysts fell to the sidelines weighing in on Seagen (SGENResearch Report), Crispr Therapeutics AG (CRSPResearch Report) and Merck & Company (MRKResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Seagen (SGEN)

In a report issued on July 29, Kennen MacKay from RBC Capital maintained a Hold rating on Seagen, with a price target of $148.00. The company’s shares closed last Friday at $153.39.

According to TipRanks.com, MacKay is a 4-star analyst with an average return of 12.9% and a 56.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Acceleron Pharma, and Agios Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seagen with a $187.00 average price target, which is a 23.0% upside from current levels. In a report issued on July 16, Morgan Stanley also maintained a Hold rating on the stock with a $167.00 price target.

See today’s analyst top recommended stocks >>

Crispr Therapeutics AG (CRSP)

RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG on July 30 and set a price target of $117.00. The company’s shares closed last Friday at $121.02.

According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 31.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Intellia Therapeutics.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $163.22, representing a 33.3% upside. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $139.00 price target.

Merck & Company (MRK)

In a report issued on July 29, Daniel Busby from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $80.00. The company’s shares closed last Friday at $76.87.

According to TipRanks.com, Busby is a 1-star analyst with an average return of -6.1% and a 33.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $93.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SGEN:

Tags: